MannKind Corporation (MNKD)
Symbol Info
Listed Symbol MNKD
Name MannKind Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $27,859,000
Latest Fiscal EPS $-0.61
Price Info
21 Day Moving Average $1.2257
21 Day EMA $1.262160
50 Day Moving Average $1.1521
50 Day EMA $1.208730
200 Day EMA $1.382740
200 Day Moving Average 1.391300
52 Week High $2.34
52 Week Low $0.94
52 Week Change $-21.428600
Alpha -0.033842
Beta 2.3544
Standard Deviation 0.273270
R2 0.088004
Periods 60
Share Information
10 Day Average Volume 3,041,812
20 Day Average Volume 2,681,043
30 Day Average Volume 2,638,716
50 Day Average Volume 2,373,349
Outstanding Shares 189,616,126
Float Shares 184,927,047
Percent Float 97.53%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 201
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 4,701,819
Institute Holdings Percent 39.100000
Institute Sold Previous 3 Months 8,636,018
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,689,079
Price Change
7 Day Price Change $-0.05
7 Day Percent Change -3.65%
21 Day Price Change $0.2200000
21 Day Percent Change 20.00%
30 Day Price Change $0.1750001
30 Day Percent Change 15.28%
Month To Date Price Change $0.2200
Month To Date Percent 20.00%
90 Day Price Change $0.160000
90 Day Percent Change 13.79%
Quarter To Date $0.170000
Quarter To Date Percent 14.78%
180 Day Price Change $-0.89
180 Day Percent Change -40.27%
200 Day Price Change $-0.4
200 Day Percent Change -23.26%
Year To Date $0.260000
Year To Date Percent 24.53%
Profile
Description MannKind Corp is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of therapeutic products and solutions for the patients with the diseases such as diabetes. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, Oral inhalers and others. The company has following products in the pipeline: Epinephrine technosphere, Treprostinil technosphere, and Palonosetron technosphere.
Details
Issue Type CS
Market Cap $250,293,286
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 189,616,126
CEO Michael E. Castagna
Employees 225
Last Audit UE
Classification
CIK 0000899460
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
Website http://www.mannkindcorp.com
Facisimile
Telephone +1 818 661-5000
Email
Key Ratios
Profitability
EBIT Margin -102.1
EBITDA Margin -96.9
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 55.80
Profit Margin TOT -
Income Statements
Revenue $53,004,000
Revenue Per Share $0.2795
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $335,665,576
Price To Sales 4.722159
Price To Free Cash -12
PE High Last 5 Years -
Price To Book 187.9
Price To Cash Flow 26.5
PE Low Last 5 Years -
Price To Tangible Book -1.4
Financial Strength
Total Debt To Equity -
Int Coverage -7.6
Current Ratio 0.6
Leverage Ratio -0.4
Quick Ratio 0.5
Long Term Debt To Capital -
Assets
Receivables Turnover 13.9
Invoice Turnover 6.20
Assets Turnover 0.70
Management Effectiveness
Return Assets -85.94
Return On Equity 30.79
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
MNKD
MannKind
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.